SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechNavio | PRODUCT CODE: 2172677

Cover Image

PUBLISHER: TechNavio | PRODUCT CODE: 2172677

Global Tourettes Syndrome Drugs Market 2026-2030

PUBLISHED:
PAGES: 287 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2500
PDF (Enterprise License)
USD 4000

Add to Cart

The global tourettes syndrome drugs market is forecasted to grow by USD 739.6 mn during 2025-2030, accelerating at a CAGR of 6.9% during the forecast period. The report on the global tourettes syndrome drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in neurobiological research and targeted drug development, rising global awareness and enhanced diagnostic capabilities, favorable regulatory environments and financial incentives for orphan drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year2025
End Year2030
Series Year2026-2030
Growth MomentumAccelerate
YOY 20266.6%
CAGR6.9%
Incremental Value$739.6 mn

Technavio's global tourettes syndrome drugs market is segmented as below:

By Product

  • Antipsychotics
  • Non-antipsychotics

By Distribution Channel

  • Offline
  • Online

By Application

  • Children
  • Adults

Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • The Netherlands
  • Asia
  • Rest of World (ROW)
  • Rest of World (ROW)

This study identifies the evolution of non-dopaminergic pharmacological interventions as one of the prime reasons driving the global tourettes syndrome drugs market growth during the next few years. Also, integration of digital therapeutics and wearable monitoring technologies and strategic focus on precision medicine and pharmacogenomic tailoring will lead to sizable demand in the market.

The report on the global tourettes syndrome drugs market covers the following areas:

  • Global tourettes syndrome drugs market sizing
  • Global tourettes syndrome drugs market forecast
  • Global tourettes syndrome drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global tourettes syndrome drugs market vendors that include AstraZeneca Plc, Bausch Health Co Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Catalyst Pharmaceuticals Inc., Eli Lilly and Co., H. Lundbeck AS, Ionis Pharmaceuticals Inc., Johnson and Johnson, Kyowa Kirin Co. Ltd., Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co Ltd., Sun Pharmaceutical Industries, Synendos Therapeutics AG, Tasly Pharmaceutical Group Co., Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global tourettes syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR75738

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market by Geography
    • Executive Summary - Chart on Market Segmentation by Product
    • Executive Summary - Chart on Market Segmentation by Distribution Channel
    • Executive Summary - Chart on Market Segmentation by Application
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

  • 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • 2.2 Criticality of inputs and Factors of differentiation
  • 2.3 Factors of disruption
  • 2.4 Impact of drivers and challenges

3 Market Landscape

  • 3.1 Market ecosystem
  • 3.2 Market characteristics
  • 3.3 Value chain analysis

4 Market Sizing

  • 4.1 Market definition
  • 4.2 Market segment analysis
    • Market segments
  • 4.3 Market size 2025
  • 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

  • 5.1 Global Tourettes Syndrome Drugs Market 2020 - 2024
    • Historic Market Size - Data Table on Global Tourettes Syndrome Drugs Market 2020 - 2024 ($ million)
  • 5.2 Product segment analysis 2020 - 2024
    • Historic Market Size - Product Segment 2020 - 2024 ($ million)
  • 5.3 Distribution Channel segment analysis 2020 - 2024
    • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
  • 5.4 Application segment analysis 2020 - 2024
    • Historic Market Size - Application Segment 2020 - 2024 ($ million)
  • 5.5 Geography segment analysis 2020 - 2024
    • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
  • 5.6 Country segment analysis 2020 - 2024
    • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

  • 6.1 Impact of AI on Global Tourettes Syndrome Drugs Market
  • 6.2 Impact of Geopolitical Conflicts on Global Tourettes Syndrome Drugs Market

7 Five Forces Analysis

  • 7.1 Five forces summary
    • Five forces analysis - Comparison between 2025 and 2030
  • 7.2 Bargaining power of buyers
    • Bargaining power of buyers - Impact of key factors 2025 and 2030
  • 7.3 Bargaining power of suppliers
    • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
  • 7.4 Threat of new entrants
    • Threat of new entrants - Impact of key factors in 2025 and 2030
  • 7.5 Threat of substitutes
    • Threat of substitutes - Impact of key factors in 2025 and 2030
  • 7.6 Threat of rivalry
    • Threat of rivalry - Impact of key factors in 2025 and 2030
  • 7.7 Market condition

8 Market Segmentation by Product

  • 8.1 Market segments
  • 8.2 Comparison by Product
  • 8.3 Antipsychotics - Market size and forecast 2025-2030
  • 8.4 Non-antipsychotics - Market size and forecast 2025-2030
  • 8.5 Market opportunity by Product
    • Market opportunity by Product ($ million)

9 Market Segmentation by Distribution Channel

  • 9.1 Market segments
  • 9.2 Comparison by Distribution Channel
  • 9.3 Offline - Market size and forecast 2025-2030
  • 9.4 Online - Market size and forecast 2025-2030
  • 9.5 Market opportunity by Distribution Channel
    • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Application

  • 10.1 Market segments
  • 10.2 Comparison by Application
  • 10.3 Children - Market size and forecast 2025-2030
  • 10.4 Adults - Market size and forecast 2025-2030
  • 10.5 Market opportunity by Application
    • Market opportunity by Application ($ million)

11 Customer Landscape

  • 11.1 Customer landscape overview
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

  • 12.1 Geographic segmentation
  • 12.2 Geographic comparison
  • 12.3 North America - Market size and forecast 2025-2030
    • 12.3.1 US - Market size and forecast 2025-2030
    • 12.3.2 Canada - Market size and forecast 2025-2030
    • 12.3.3 Mexico - Market size and forecast 2025-2030
  • 12.4 Europe - Market size and forecast 2025-2030
    • 12.4.1 UK - Market size and forecast 2025-2030
    • 12.4.2 Germany - Market size and forecast 2025-2030
    • 12.4.3 France - Market size and forecast 2025-2030
    • 12.4.4 Italy - Market size and forecast 2025-2030
    • 12.4.5 Spain - Market size and forecast 2025-2030
    • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.5 Asia - Market size and forecast 2025-2030
    • 12.5.1 China - Market size and forecast 2025-2030
    • 12.5.2 Japan - Market size and forecast 2025-2030
    • 12.5.3 India - Market size and forecast 2025-2030
    • 12.5.4 South Korea - Market size and forecast 2025-2030
    • 12.5.5 Indonesia - Market size and forecast 2025-2030
    • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
    • 12.6.1 Brazil - Market size and forecast 2025-2030
    • 12.6.2 Turkey - Market size and forecast 2025-2030
    • 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
    • 12.6.4 South Africa - Market size and forecast 2025-2030
    • 12.6.5 Israel - Market size and forecast 2025-2030
    • 12.6.6 UAE - Market size and forecast 2025-2030
    • 12.6.7 Argentina - Market size and forecast 2025-2030
    • 12.6.8 Colombia - Market size and forecast 2025-2030
  • 12.7 Market opportunity by geography
    • Market opportunity by geography ($ million)
    • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

  • 13.1 Market drivers
    • Advancements in neurobiological research and targeted drug development
    • Rising global awareness and enhanced diagnostic capabilities
    • Favorable regulatory environments and financial incentives for orphan drugs
  • 13.2 Market challenges
    • Diagnostic ambiguity and pathophysiological complexity
    • Regulatory constraints and clinical trial vulnerabilities
    • Suboptimal safety profiles and patient non-adherence
  • 13.3 Impact of drivers and challenges
    • Impact of drivers and challenges in 2025 and 2030
  • 13.4 Market opportunities
    • Evolution of non-dopaminergic pharmacological interventions
    • Integration of digital therapeutics and wearable monitoring technologies
    • Strategic focus on precision medicine and pharmacogenomic tailoring

14 Competitive Landscape

  • 14.1 Overview
  • 14.2 Competitive Landscape
    • Overview on criticality of inputs and factors of differentiation
  • 14.3 Landscape disruption
    • Overview on factors of disruption
  • 14.4 Industry risks
    • Impact of key risks on business

15 Competitive Analysis

  • 15.1 Companies profiled
    • Companies covered
  • 15.2 Company ranking index
    • Company ranking index
  • 15.3 Market positioning of companies
    • Matrix on companies position and classification
  • 15.4 AstraZeneca Plc
    • AstraZeneca Plc - Overview
    • AstraZeneca Plc - Business segments
    • AstraZeneca Plc - Key news
    • AstraZeneca Plc - Key offerings
    • AstraZeneca Plc - Segment focus
    • SWOT
  • 15.5 Bausch Health Co Inc.
    • Bausch Health Co Inc. - Overview
    • Bausch Health Co Inc. - Business segments
    • Bausch Health Co Inc. - Key offerings
    • Bausch Health Co Inc. - Segment focus
    • SWOT
  • 15.6 Biogen Inc.
    • Biogen Inc. - Overview
    • Biogen Inc. - Product / Service
    • Biogen Inc. - Key news
    • Biogen Inc. - Key offerings
    • SWOT
  • 15.7 Bristol Myers Squibb Co.
    • Bristol Myers Squibb Co. - Overview
    • Bristol Myers Squibb Co. - Product / Service
    • Bristol Myers Squibb Co. - Key news
    • Bristol Myers Squibb Co. - Key offerings
    • SWOT
  • 15.8 Eli Lilly and Co.
    • Eli Lilly and Co. - Overview
    • Eli Lilly and Co. - Product / Service
    • Eli Lilly and Co. - Key news
    • Eli Lilly and Co. - Key offerings
    • SWOT
  • 15.9 H. Lundbeck AS
    • H. Lundbeck AS - Overview
    • H. Lundbeck AS - Product / Service
    • H. Lundbeck AS - Key offerings
    • SWOT
  • 15.10 Ionis Pharmaceuticals Inc.
    • Ionis Pharmaceuticals Inc. - Overview
    • Ionis Pharmaceuticals Inc. - Product / Service
    • Ionis Pharmaceuticals Inc. - Key news
    • Ionis Pharmaceuticals Inc. - Key offerings
    • SWOT
  • 15.11 Johnson and Johnson
    • Johnson and Johnson - Overview
    • Johnson and Johnson - Business segments
    • Johnson and Johnson - Key news
    • Johnson and Johnson - Key offerings
    • Johnson and Johnson - Segment focus
    • SWOT
  • 15.12 Kyowa Kirin Co. Ltd.
    • Kyowa Kirin Co. Ltd. - Overview
    • Kyowa Kirin Co. Ltd. - Business segments
    • Kyowa Kirin Co. Ltd. - Key offerings
    • Kyowa Kirin Co. Ltd. - Segment focus
    • SWOT
  • 15.13 Neurocrine Biosciences Inc.
    • Neurocrine Biosciences Inc. - Overview
    • Neurocrine Biosciences Inc. - Product / Service
    • Neurocrine Biosciences Inc. - Key offerings
    • SWOT
  • 15.14 Novartis AG
    • Novartis AG - Overview
    • Novartis AG - Business segments
    • Novartis AG - Key news
    • Novartis AG - Key offerings
    • Novartis AG - Segment focus
    • SWOT
  • 15.15 Sun Pharmaceutical Industries
    • Sun Pharmaceutical Industries - Overview
    • Sun Pharmaceutical Industries - Business segments
    • Sun Pharmaceutical Industries - Key news
    • Sun Pharmaceutical Industries - Key offerings
    • Sun Pharmaceutical Industries - Segment focus
    • SWOT
  • 15.16 Tasly Pharmaceutical Group Co.
    • Tasly Pharmaceutical Group Co. - Overview
    • Tasly Pharmaceutical Group Co. - Product / Service
    • Tasly Pharmaceutical Group Co. - Key offerings
    • SWOT
  • 15.17 Teva Pharmaceutical Ltd.
    • Teva Pharmaceutical Ltd. - Overview
    • Teva Pharmaceutical Ltd. - Business segments
    • Teva Pharmaceutical Ltd. - Key news
    • Teva Pharmaceutical Ltd. - Key offerings
    • Teva Pharmaceutical Ltd. - Segment focus
    • SWOT
  • 15.18 Viatris Inc.
    • Viatris Inc. - Overview
    • Viatris Inc. - Business segments
    • Viatris Inc. - Key news
    • Viatris Inc. - Key offerings
    • Viatris Inc. - Segment focus
    • SWOT

16 Appendix

  • 16.1 Scope of the report
    • Market definition
    • Objectives
    • Notes and caveats
  • 16.2 Inclusions and exclusions checklist
    • Inclusions checklist
    • Exclusions checklist
  • 16.3 Currency conversion rates for US$
    • Currency conversion rates for US$
  • 16.4 Research methodology
    • Research methodology
  • 16.5 Data procurement
    • Information sources
  • 16.6 Data validation
    • Data validation
  • 16.7 Validation techniques employed for market sizing
    • Validation techniques employed for market sizing
  • 16.8 Data synthesis
    • Data synthesis
  • 16.9 360 degree market analysis
    • 360 degree market analysis
  • 16.10 List of abbreviations
    • List of abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!